Rising Prevalence of Acute Chronic Disorders and Diseases in Individuals Globally is a Factor Responsible for the Growth of the Global Acute Coronary Syndrome Market

According to the world health organization, acute coronary syndrome is responsible for more than 1.8 million deaths per year. Non-ST-elevation myocardial infarction (NSTEMI), ST-elevation MI (STEMI), and unstable angina are the three prevalent types of acute coronary syndrome. Smoking, high blood pressure, high alcohol consumption, diabetes and obesity are the common causes of acute coronary syndrome.

Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/global-acute-coronary-syndrome-market

Global acute coronary syndrome market is expected to reach USD 14,810.38 million by 2029 from USD 10,023.99 million in 2021, with a CAGR of 5.2% in the forecast period of 2022 to 2029. Increasing demand for advanced medical technologies for diagnostic and treatment purposes and the growing incidence rate of acute coronary syndrome are some of the drivers boosting the growth of the acute coronary syndrome market. With the increasing consumption of sugar and sugar-related products, increasing awareness about the availability of treatment options in the developing economies and rising personal disposable income are some other important market growth determinants.

Rise in the geriatric population base globally is expected to drive the market's growth rate

The geriatric population is the most susceptible to developing chronic diseases and disorders. Therefore, rising geriatric populace all around the world is extremely vulnerable to developing coronary artery disease, ischemic heart, and vascular disease. This in turn will act as an important market growth determinant. Increased expenditure by public and private players on the development of healthcare infrastructure will also promote the market growth rate. Continuous research and development pertaining to the deployment of advanced healthcare technologies will yet again widen the scope of growth.

Report Scope and Market Segmentation

Segment Analysis:

The global acute coronary syndrome market is categorized based on type, diagnosis, treatment and end user.

• On the basis of type, global acute coronary syndrome market is segmented into Non-St-Elevation Myocardial Infarction, St-Elevation Myocardial Infarction and Unstable Angina. In 2022, Non-St-Elevation Myocardial Infarction segment is expected to dominate the global acute coronary syndrome market with 58.7% market share due to increase in prevalence of coronary disease among adults and geriatric population in the global acute coronary syndrome market. However, low awareness of disease management in low economic countries may hamper the global acute coronary syndrome market growth.
• On the basis of diagnosis, global acute coronary syndrome market is segmented into stress test, blood tests, imaging and others. In 2022, stress test segment is expected to dominate the global acute coronary syndrome market with 66.8% market share because of its availability in every primary healthcare institutions and it’s cost-effectiveness.
• On the basis of treatment, global acute coronary syndrome market is segmented into medication and surgery. In 2022, medication segment is expected to dominate the global acute coronary syndrome market with 60.9% market share because of its better patient compliance offered through medications.

Medication is expected to dominate the end user segment in the global acute coronary syndrome market

In 2022, the medication segment will emerge as the dominating segment. This is because of the rising number of drug trials and drug approval procedures especially in the developing economies. Further, surging expenditure to undertake research and development proficiencies pertaining to the deployment of advanced healthcare technologies will also push the growth of this segment. 

• On the basis of end user, global acute coronary syndrome market is segmented into hospitals and clinics, diagnostic centers, academic institutes and others. In 2022, hospitals and clinics segment is expected to dominate the global acute coronary syndrome market with 65.6% market share because of better and effective treatment with advance diagnostics tools under skilled professional healthcare people.

Hospitals and clinics is expected to dominate the end user segment in the global acute coronary syndrome market

Rising number of hospitals and clinics all especially in the developing economies has emerged as a major factor responsible for bolstering the growth of this segment. The hospitals and clinics segment is projected to hold more than 65% of the total end user segment share. This is because of the rising awareness about the availability of treatment options and increasing incidence rate of acute coronary syndrome globally. 

Major Players

Data Bridge Market Research recognizes the following companies as the major sulfuric acid market players in advanced wound care market are Pfizer Inc. (U.S.), Merck & Co. Inc. (Germany), Regeneron Pharmaceuticals Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany) and Johnson & Johnson Services, Inc. (U.S.).

Market Development

• In October 2021, Novartis AG expanded a new digital healthcare solution across chronic heart disease management. Co-developed with China’s internet multinational Tencent and leading Chinese medical organizations, the digital healthcare solution is now broadening its scope to cardiovascular disease in general – supporting patients from pre-diagnosis to hospital discharge and ongoing at-home disease management. It helps patients with heart failure to easily accommodate disease management into everyday living, alerting them to signs of disease worsening. Patients can then take early action to avoid re-hospitalization, in a country where heart disease is on the rise.
• Pfizer launched Zirabev, a bevacizumab biosimilar, in the United States in January 2020. ZIRABEVTM (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab), has been approved by the US Food and Drug Administration (FDA) for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell, and persistent, recurrent or metastatic cervical cancer.
• Merck announced the effective conclusion of its acquisition of Acceleron Pharma Inc. in November 2021. It's a critical and strategic opportunity for the company to expand its cardiovascular portfolio and pipeline, which builds on its long and illustrious history in cardiovascular disease and supports its business development strategy, fueled by Acceleron's groundbreaking research.

Regional Analysis

Geographically, the countries covered in the acute coronary syndrome market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in acute coronary syndrome market during the forecast period 2022 - 2029

North America dominates the global acute coronary syndrome market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. The U.S. is dominating due to the presence of major market players which provide the wide drug portfolio and well-developed healthcare infrastructure in this region. Also, existence of advanced healthcare technologies in this region is another reason for this region’s dominance in the global market.   

Asia-Pacific is estimated to be the fastest-growing region in acute coronary syndrome market the forecast period 2022 - 2029

Asia-Pacific is expected to grow during the forecast period due to the increasing patient population and rapid development of infrastructural facilities in emerging economies in this region. In addition to this, rising private and public expenditure on the development of healthcare industry infrastructure in the developing and backward economies and increasing per-capita income are expected to propel the market's growth rate in this region. Also, the increasing geriatric population base, surging incidence rate of chronic and acute disorders and diseases, and rising medical tourism are important market growth determinants.

COVID-19 Impact Analysis

COVID-19 brought an epidemic on the industries especially the healthcare industry. Restrictions imposed on the transportation and movement all together negatively impacted the market. Further disruptions in the supply chain, including logistics, storage and warehousing impacted the drug delivery and medical devices and technologies transportation. This resulted in negatively impacting the acute coronary syndrome. Further, all the healthcare or medical resources were driven towards meeting the needs and demands arising out of COVID-19 emergencies. During this tenure, surgical procedures, medical meetings and conferences, and unnecessary medical activities were all postponed.

For more detailed information about the acute coronary syndrome market report, click here – https://www.databridgemarketresearch.com/fr/reports/global-acute-coronary-syndrome-market